Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IRD Opus Genetics	$0.98 -4.3%	$0.96	$0.65 ▼ $1.75	$58.27M	N/A	525,895 shs	783,289 shs
NTEC Intec Pharma		$13.52	$8.80 ▼ $36.88	$8.65M	0.83	543,436 shs	988,300 shs
OSTX OS Therapies	$1.84 +1.7%	$1.76	$1.12 ▼ $7.00	$51.70M	N/A	458,635 shs	254,659 shs
RVPH Reviva Pharmaceuticals	$0.34 -5.7%	$0.83	$0.30 ▼ $4.28	$16.20M	0.11	1.30 million shs	11.47 million shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IRD Opus Genetics	0.00%	+2.79%	-2.66%	-0.53%	+97,659,900.00%
NTEC Intec Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
OSTX OS Therapies	0.00%	+3.37%	+20.26%	+19.48%	+183,999,900.00%
RVPH Reviva Pharmaceuticals	0.00%	-51.91%	-65.21%	-64.62%	-73.63%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IRD Opus Genetics	1.8137 of 5 stars	3.5	0.0	0.0	0.0	2.4	0.0	0.6
NTEC Intec Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	2.366 of 5 stars	3.7	0.0	0.0	0.0	1.8	1.7	0.6
RVPH Reviva Pharmaceuticals	2.7633 of 5 stars	3.6	1.0	0.0	0.0	2.4	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IRD Opus Genetics	3.00	Buy	$7.33	650.90% Upside
NTEC Intec Pharma	0.00	N/A	N/A	N/A
OSTX OS Therapies	3.40	Buy	$18.00	878.26% Upside
RVPH Reviva Pharmaceuticals	3.29	Buy	$9.00	2,566.67% Upside

Current Analyst Ratings Breakdown

Latest NTEC, RVPH, OSTX, and IRD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/27/2025	IRD Opus Genetics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/27/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
6/24/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/9/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/3/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
5/20/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $3.00
5/15/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/24/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
4/22/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/11/2025	IRD Opus Genetics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IRD Opus Genetics	$13.65M	4.27	N/A	N/A	$0.21 per share	4.65
NTEC Intec Pharma	N/A	N/A	N/A	N/A	$16.18 per share	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	$0.02 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IRD Opus Genetics	-$57.53M	-$2.10	N/A	N/A	N/A	-429.42%	-283.28%	-144.32%	8/12/2025 (Estimated)
NTEC Intec Pharma	-$14.13M	-$16.32	N/A	N/A	N/A	N/A	-96.37%	-68.87%	N/A
OSTX OS Therapies	-$7.79M	-$0.86	N/A	N/A	N/A	N/A	N/A	-569.57%	N/A
RVPH Reviva Pharmaceuticals	-$29.92M	-$0.79	N/A	N/A	N/A	N/A	N/A	-302.31%	8/13/2025 (Estimated)

Latest NTEC, RVPH, OSTX, and IRD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	IRD Opus Genetics	-$0.34	-$0.32	+$0.02	-$0.24	$4.00 million	$4.30 million
5/15/2025	Q1 2025	RVPH Reviva Pharmaceuticals	-$0.21	-$0.13	+$0.08	-$0.13	N/A	N/A
3/31/2025	Q4 2024	IRD Opus Genetics	-$0.34	-$1.27	-$0.93	-$1.27	$11.10 million	$3.40 million
3/31/2025	Q4 2024	RVPH Reviva Pharmaceuticals	-$0.22	-$0.15	+$0.07	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IRD Opus Genetics	N/A	N/A	N/A	N/A	N/A
NTEC Intec Pharma	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IRD Opus Genetics	N/A	1.98	1.98
NTEC Intec Pharma	N/A	2.34	2.34
OSTX OS Therapies	N/A	0.76	0.76
RVPH Reviva Pharmaceuticals	N/A	0.54	0.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IRD Opus Genetics	14.97%
NTEC Intec Pharma	22.37%
OSTX OS Therapies	N/A
RVPH Reviva Pharmaceuticals	63.18%

Insider Ownership

Company	Insider Ownership
IRD Opus Genetics	6.60%
NTEC Intec Pharma	3.30%
OSTX OS Therapies	13.80%
RVPH Reviva Pharmaceuticals	27.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IRD Opus Genetics	14	59.66 million	55.72 million	N/A
NTEC Intec Pharma	40	898,000	N/A	Optionable
OSTX OS Therapies	N/A	28.10 million	N/A	N/A
RVPH Reviva Pharmaceuticals	5	48.00 million	34.96 million	Optionable

NTEC, RVPH, OSTX, and IRD Headlines

Recent News About These Companies

Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Investing.com

June 29 at 8:33 AM | investing.com

Reviva Dives on Stock Offering

June 26, 2025 | baystreet.ca

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

June 26, 2025 | globenewswire.com

Reviva Pharmaceuticals stock falls after announcing public offering

June 25, 2025 | za.investing.com

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

June 25, 2025 | globenewswire.com

RVPH: Open Label Extension Results & Key Opinion Leader Discussion

June 5, 2025 | finance.yahoo.com

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 5, 2025 | globenewswire.com

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

June 2, 2025 | globenewswire.com

Reviva to Participate in Upcoming Investor Conferences in May 2025

May 20, 2025 | santelog.comS

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 15, 2025 | globenewswire.com

Reviva to Participate in the A.G.P. Healthcare Company Showcase

May 13, 2025 | finance.yahoo.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Icon (ICLR), Reviva Pharmaceuticals Holdings (RVPH) and SurModics (SRDX)

May 4, 2025 | theglobeandmail.com

Reviva to Participate in the Citizens Life Sciences Conference

April 29, 2025 | finance.yahoo.com

RVPH: M&A Deals Highlight Brilaroxazine Value

April 7, 2025 | finance.yahoo.com

Roth MKM Reaffirms Their Buy Rating on Reviva Pharmaceuticals Holdings (RVPH)

April 5, 2025 | markets.businessinsider.com

Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

March 31, 2025 | markets.businessinsider.com

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

March 30, 2025 | globenewswire.com

Why Reviva Pharmaceuticals Holdings, Inc.’s (RVPH) Stock Is Down 10.61%

March 7, 2025 | aaii.comA

Unusually active option classes on open February 12th

February 12, 2025 | markets.businessinsider.com

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 4, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
Is Affirm Stock Buy Now, Profit Later or Buy Now, Pay Later?
By Jeffrey Neal Johnson | June 6, 2025
View Is Affirm Stock Buy Now, Profit Later or Buy Now, Pay Later?
Top 4 Growth Stocks With Momentum and Room to Run
By Ryan Hasson | June 16, 2025
View Top 4 Growth Stocks With Momentum and Room to Run

NTEC, RVPH, OSTX, and IRD Company Descriptions

Opus Genetics NASDAQ:IRD

$0.98 -0.04 (-4.25%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.93 -0.05 (-4.77%)

As of 09:26 AM Eastern

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

Intec Pharma NASDAQ:NTEC

Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel.

OS Therapies NYSE:OSTX

$1.84 +0.03 (+1.66%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.87 +0.03 (+1.63%)

As of 09:27 AM Eastern

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

Reviva Pharmaceuticals NASDAQ:RVPH

$0.34 -0.02 (-5.73%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.35 +0.01 (+3.70%)

As of 09:25 AM Eastern

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time